Search…

Lates News

13/11/2025

On November 13th, the official website of the China Drug Administration (CDE) announced that the new indication application for the Glucagon-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) dual receptor agonist Tirzepatide injection of Eli Lilly (LLY.N) has been accepted. This is the third indication approved for the drug in China after receiving approval for another indication.

Latest

1 m ago

Lok Hing Testing (01586.HK) spent HK$11,000 on November 13 to repurchase 4,000 shares.

2 m ago

CRIC Real Estate Research: The transaction volume of foreclosed houses in October maintained at a high level for the year, and the transaction rate has returned to over 20% as expected.

2 m ago

JD's stock market in the U.S. saw an increase in pre-market trading, with the company's revenue in the third quarter surpassing expectations, leading to a 4.7% increase.

2 m ago

SMIC International: In the third quarter, the company achieved a total operating income of 17.162 billion yuan, an increase of 6.9% compared to the previous quarter; the company's gross margin was 25.5%, an increase of 4.8 percentage points compared to the previous quarter; and the capacity utilization rate increased to 95.8%, an increase of 3.3 percentage points compared to the previous quarter.

3 m ago

SMIC International: Asset impairment loss of 917 million yuan was provided in the first three quarters before 2025.

See all latest